Evidence map›Paper›PMID 39284813›Full record

ArticleScientific reports2024

Leveraging immuno-fluorescence data to reduce pathologist annotation requirements in lung tumor segmentation using deep learning.

Hatef Mehrabian, Jens Brodbeck, Peipei Lyu, Edith Vaquero, Abhishek Aggarwal, Lauri Diehl

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hatef MehrabianNon-Clinical Safety and Pathobiology, Gilead Sciences, Foster City, CA, USA. hatef.mehrabian@gilead.com.
Jens BrodbeckNon-Clinical Safety and Pathobiology, Gilead Sciences, Foster City, CA, USA.
Peipei LyuNon-Clinical Safety and Pathobiology, Gilead Sciences, Foster City, CA, USA.
Edith VaqueroNon-Clinical Safety and Pathobiology, Gilead Sciences, Foster City, CA, USA.
Abhishek AggarwalNon-Clinical Safety and Pathobiology, Gilead Sciences, Foster City, CA, USA.
Lauri DiehlNon-Clinical Safety and Pathobiology, Gilead Sciences, Foster City, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main bottleneck in training a robust tumor segmentation algorithm for non-small cell lung cancer (NSCLC) on H&E is generating sufficient ground truth annotations. Various approaches for generating tumor labels to train a tumor segmentation model was explored. A large dataset of low-cost low-accuracy panCK-based annotations was used to pre-train the model and determine the minimum required size of the expensive but highly accurate pathologist annotations dataset. PanCK pre-training was compared to foundation models and various architectures were explored for model backbone. Proper study design and sample procurement for training a generalizable model that captured variations in NSCLC H&E was studied. H&E imaging was performed on 112 samples (three centers, two scanner types, different staining and imaging protocols). Attention U-Net architecture was trained using the large panCK-based annotations dataset (68 samples, total area 10,326 [mm

Indexed as

Carcinoma, Non-Small-Cell LungDeep LearningLung NeoplasmsPathologistsAlgorithmsHumansImage Processing, Computer-AssistedConvolutional neural network (CNN)Digital pathologyNon-small cell lung cancer (NSCLC)panCK tumor annotationTumor segmentation

Identifiers

PMID39284813
PMCPMC11405770

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.